Ultragenyx Pharmaceutical | RARE - Assets


Ultragenyx Pharmaceutical reported $1.26B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.74B 137.67M Jun/2026
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Alnylam Pharmaceuticals USD 5.56B 429.22M Jun/2026
BioCryst Pharmaceuticals USD 557.85M 92.8M Jun/2026
BioMarin Pharmaceutical USD 11.72B 3.13B Jun/2026
Immunic USD 189.74M 165.69M Mar/2026
Insmed USD 2.1B 26.7M Jun/2026
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
Kyowa Hakko Kirin JPY 1.13T 63.78B Jun/2026
MacroGenics USD 217.87M 38.97M Mar/2026
Moderna USD 10.96B 527M Jun/2026
Neurocrine Biosciences USD 5.36B 452.9M Jun/2026
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 41.73B 861.8M Jun/2026
Sarepta Therapeutics USD 3.19B 9.58M Jun/2026
Ultragenyx Pharmaceutical USD 1.26B 32M Jun/2026
Vertex Pharmaceuticals USD 27.42B 938.9M Jun/2026